Memantine in Body Focused Repetitive Behaviors

Recruiting in Palo Alto (17 mi)

Overseen by Jon Grant, JD, MD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Chicago

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests whether memantine can help adults with trichotillomania or skin picking disorder by balancing brain activity to reduce their urges. Participants will take memantine for a period of time to see if it is effective and safe. Memantine has been used to treat moderate to severe Alzheimer's disease by protecting neurons from excessive stimulation.

Research Team

Jon Grant, JD, MD, MPH

Principal Investigator

University of Chicago

Eligibility Criteria

Inclusion Criteria

Ability to understand and sign the consent form.

You have current trichotillomania or skin picking disorder.

men and women age ≥18 years;

Treatment Details

Interventions

• Memantine (Glutamate receptor antagonist)
• Placebo (Behavioural Intervention)

Participant Groups

Group I: Memantine Experimental Treatment 1 Intervention

10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks

Group II: Placebo Placebo Group 1 Intervention

10mg once daily of placebo for two weeks, then 20mg for the remaining six weeks

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials

1,086

Recruited

844,000+

Pete Salzmann

University of Chicago

Chief Executive Officer since 2018

MD from University of Chicago’s Pritzker School of Medicine, MBA from Stanford University’s Graduate School of Business

Anh Nguyen

University of Chicago

Chief Medical Officer

MD from Rutgers New Jersey Medical School, MBA from University of Chicago